Veracyte Q4 revenue rises 19%, beats expectations

Veracyte

25/02/2026 21:14

Overview

Cancer diagnostics firm's Q4 revenue rose 19%, beating analyst expectations

Testing revenue grew 21% driven by Decipher and Afirma tests

Company recorded GAAP net income of $41.1 mln, up 705% yr/yr

Outlook

Veracyte expects 2026 revenue growth of 10% to 13%, reaching $570 mln to $582 mln

Company projects 2026 testing revenue to grow 14% to 16%, reaching $560 mln to $570 mln

Veracyte anticipates 2026 adjusted EBITDA margin of approximately 25%

Result Drivers

DECIPHER AND AFIRMA GROWTH - Testing revenue increased 21% driven by Decipher and Afirma tests

CASH GENERATION - Generated $52.6 million of cash from operations in Q4

Company press release: ID:nBwb1stcfa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$140.60 mln
$133.62 mln (12 Analysts)
Q4 Net Income
$41.10 mln
Q4 Gross Margin
72.50%
Q4 Adjusted Operating Expenses
$65.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Veracyte Inc is $50.00, about 40.1% above its February 24 closing price of $35.69

The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 49 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)